Heart rate and cardiovascular protection

被引：66

作者：

Caetano, Joana ^{[1
]}

Alves, Jose Delgado ^{[1
,2
]}

机构：

[1] Fernando Fonseca Hosp, Dept Med, P-2720276 Amadora, Portugal

[2] CEDOC, Ctr Chron Dis, Fac Med Sci Lisbon, P-1150082 Lisbon, Portugal

来源：

EUROPEAN JOURNAL OF INTERNAL MEDICINE | 2015年 / 26卷 / 04期

关键词：

Resting heart rate; Heart rate variability; Cardiovascular risk factors; Endothelial dysfunction; Atherosclerosis; Autonomic dysfunction; CORONARY-ARTERY-DISEASE; RATE-VARIABILITY; MYOCARDIAL-INFARCTION; CLINICAL-OUTCOMES; RATE REDUCTION; RISK-FACTOR; FOLLOW-UP; MORTALITY; FAILURE; ASSOCIATION;

D O I：

10.1016/j.ejim.2015.02.009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recent large epidemiological studies have confirmed that an elevated resting heart rate is an independent predictor of cardiovascular and overall mortality in the general population as well as in patients with hypertension, coronary heart disease and chronic heart failure. Pathophysiological studies indicate that a higher heart rate has detrimental effects that favor myocardial ischemia, ventricular arrhythmias, as well as an increase in vascular oxidative stress, endothelial dysfunction and atherosclerosis progression. Benefits of heart rate lowering drugs, such as beta-blockers and ivabradine, in reducing overall and cardiovascular-related mortality, have been demonstrated particularly in patients with coronary heart disease and heart failure. However, despite these evidences, resting heart rate is still an overlooked cardiovascular risk factor. (C) 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

引用

页码：217 / 222

页数：6

共 38 条

[1] SUBSETS OF AMBULATORY MYOCARDIAL-ISCHEMIA BASED ON HEART-RATE ACTIVITY - CIRCADIAN DISTRIBUTION AND RESPONSE TO ANTIISCHEMIC MEDICATION [J].

ANDREWS, TC ;

FENTON, T ;

TOYOSAKI, N ;

GLASSER, SP ;

YOUNG, PM ;

MACCALLUM, G ;

GIBSON, RS ;

SHOOK, TL ;

STONE, PH .

CIRCULATION, 1993, 88 (01) :92-100

[2] Efficacy of a β-adrenergic receptor antagonist, propranolol, in preventing ischaemic ventricular fibrillation:: dependence on heart rate and ischaemia duration [J].

Aupetit, JF ;

Frassati, D ;

Bui-Xuan, B ;

Freysz, M ;

Faucon, G ;

Timour, Q .

CARDIOVASCULAR RESEARCH, 1998, 37 (03) :646-655

[3] Relation of Beta-Blocker-Induced Heart Rate Lowering and Cardioprotection in Hypertension [J].

Bangalore, Sripal ;

Sawhney, Sabrina ;

Messerli, Franz H. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (18) :1482-1489

[4] Clinical Outcomes with β-Blockers for Myocardial Infarction: A Meta-analysis of Randomized Trials [J].

Bangalore, Sripal ;

Makani, Harikrishna ;

Radford, Martha ;

Thakur, Kamia ;

Toklu, Bora ;

Katz, Stuart D. ;

DiNicolantonio, James J. ;

Devereaux, P. J. ;

Alexander, Karen P. ;

Wetterslev, Jorn ;

Messerli, Franz H. .

AMERICAN JOURNAL OF MEDICINE, 2014, 127 (10) :939-953

[5] Influence of heart rate on mortality in a French population - Role of age, gender, and blood pressure [J].

Benetos, A ;

Rudnichi, A ;

Thomas, F ;

Safar, M ;

Guize, L .

HYPERTENSION, 1999, 33 (01) :44-52

[6]

Böhm M, 2010, LANCET, V376, P886, DOI 10.1016/S0140-6736(10)61259-7

[7]

Buccelletti F, 2009, EUR REV MED PHARMACO, V13, P299

[8]

Camm AJ, 1996, CIRCULATION, V93, P1043

[9] High heart rate: a cardiovascular risk factor? [J].

Cook, Stephane ;

Togni, Mario ;

Schaub, Marcus C. ;

Wenaweser, Peter ;

Hess, Otto M. .

EUROPEAN HEART JOURNAL, 2006, 27 (20) :2387-2393

[10] Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials [J].

Cucherat, Michel .

EUROPEAN HEART JOURNAL, 2007, 28 (24) :3012-3019

← 1 2 3 4 →